Suzhou Ryway Biotech
Suzhou Ryway Biotech is a peptide manufacturer based in China (Suzhou). Direct manufacturer. Holds US DMFs for semaglutide, tirzepatide, thymalfasin API.
Listing reviewed October 2026.
About Suzhou Ryway Biotech
Suzhou-based API manufacturer that says it holds more than 30 US Drug Master Files and PIC/S GMP approval. Its peptide DMFs cover semaglutide, thymalfasin and tirzepatide API. No FDA inspection is on record and the GMP approval is company-stated; no certificate seen.
Directory assessment: Suzhou Ryway Biotech is listed as a manufacturer in the peptide supply chain, serving Asia markets from China (Suzhou). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 2 sources for reference. This supplier has a medium confidence score — verification signals are present, but the listing is newer or less documented; perform standard due diligence before engaging.
- Semaglutide: DMF 40989 (Type II, active), submitted 2024-12-16
- Thymalfasin: DMF 40991 (Type II, active), submitted 2024-12-23
- Tirzepatide: DMF 41066 (Type II, active), submitted 2024-12-25
DMF numbers from the FDA quarterly DMF list. A filed DMF is not FDA approval; its contents are confidential. Reviewed 2026-10-23.